Parasomnias and Related Risk Factors


Scope of the Meeting


Parasomnias are physical events or experiences that interfere with sleep. They are characterized by abnormal behavioral or physiological events that can occur at sleep onset, during different sleep stages, or during arousals from sleep.

These disorders have seldom been investigated in the adult general population although they are estimated to be relatively common phenomena. Little is known about their prevalence and associated risk factors in the general population. Our knowledge about prevalence and incidence of parasomnias is limited compared to dyssomnias. Most of the available data are based on the main symptoms of parasomnias not the diagnoses. Furthermore, not all behaviors that occur during sleep can be classified as a parasomnia event. Additional understanding is needed to help define how best to assess these events, their severity, and potential for impact on patient safety.

Information about associated factors and triggers of a parasomnia episode is also limited as are the data related to the prevalence and relative frequency of events that are benign in nature versus those that could be considered more serious (e.g., sleep driving or sleep walking with a fall risk). Consequences on daytime functioning and emotional distress experienced following a parasomnia episode are undocumented at the epidemiological level. Therefore, it is difficult to ascertain what proportion of these individuals are truly in need of treatment. At the genetic level, there is some evidence that parasomnias may have a genetic component. Therefore, epidemiological genetic links need to be studied. Ethnicity also could play a role in some parasomnias. However, with the exception of sleep paralysis, the role of race has not been investigated. At the pharmacological level, there is some suggestion that psychotropic medications and certain premorbid behaviors related to medication use may have a role in the occurrence of some parasomnia episodes. The importance of this association remains undocumented at the epidemiological level and is in need of further study.

As many factors appear to influence the occurrence of parasomnias, identification of specific risk factors (e.g., family history, medical history, medications, sleep deprivation) is required.

Program

Saturday, June 25, 2011

08:15 – 08:30 Maurice Ohayon, MD, DSc, PhD
Opening remarks
 
08:30 – 08:50 Maurice Ohayon, MD, DSc, PhD
Epidemiology of nocturnal awakenings
 
09:00 – 09:20 Seung Chul Hong, MD, PhD
Prevalence and Risk Factors of Parasomnias In Asia
 
09:30 – 09:50 Michael Thorpy, MD
A video presentation of Parasomnias
 
10:00 - 10:15 Break
 
10:15 – 10:35 David Gozal, MD
Parasomnias in Children: A Virtually Unexplored Area of Sleep
 
10:45 – 11:05 Michael Vitiello, PhD
Parasomnias in Older Adults
 
11:15 – 12:05 Christian Guilleminault, MD
NREM Parasomnia and Sleep Instability
 
12:15 - 13:30 Lunch
 
13:30 – 13:50 Ronald Chervin, MD, MS
Polysomnographic Assessment for REM Sleep Behavior Disorder
 
14:00 – 14:20 Colin Shapiro, MD, PhD
Sleep markers and the utility of sleep recordings in Parasomnias
 
14:30 - 14:50 Ruth Benca, MD, PhD
Application of high resolution EEG to the study of parasomnias
 
15:00 – 15:20 Kenneth Lichstein, PhD
Confusional Arousals
 
15:30 – 15:50 Mark Pressman, PhD
Sleep Driving: Sleepwalking Variant, Residual Drug Effect or Both?
 
16:00 - 16:15 Break
 
16:15 – 16:35 Mark Mahowald, MD
Violent Parasomnias
 
16:45 – 17:05 Thomas Neylan, MD
Posttraumatic Parasomnia
 
17:15 – 17:35 Ruth O’Hara, PhD.
Restless Leg Syndrome: Elevation to its own Diagnostic Category in DSM-5
 
17:45 – 18:05 Andrew Krystal, MD
Are Hypnotic Medications A Risk Factor for Parasomnias?
 
18:15 – 18:35 Phyllis Zee, MD, PhD
Circadian Rhythms: Role in Parasomnias?
 
18:45 – 19:00 Maurice Ohayon, MD, DSc, PhD
Conclusions

Sunday, June 26th, 2011

08:45 - 09:00 Overview of the Symposium
 
08:15 - 10:00 General Discussion
 
10:00 - 10:30 Closing Statements

Presentation Abstracts

Click here

This activity is supported by an Educational Grant from Neurocrine Biosciences to Stanford University.